NEW YORK — Onco360 is joining the limited-distribution network for two newly approved cancer drugs made by GlaxoSmithKline, the specialty pharmacy company said.
The New York-based company said it had been selected as a distributor of Tafinlar (dabrafenib) and Mekinist (trametinib). The drugs were approved as standalone therapies, not a combined therapy.
"I'm proud that GSK continues to select our organization as a pharmacy provider for their limited-distribution products," Onco360 CEO Burt Zweigenhaft said. "Onco360 is the comprehensive and trusted source for oncology pharmaceutical needs, and we are dedicated to advancing the continuum of pharmaceutical cancer care."